**BioVision** 2/13

PRODUCT: PCI 34051

ALTERNATE NAME: N-hydroxy-1-[(4-methoxyphenyl)methyl]-1H-indole-6-

carboxamide

**CATALOG #:** 2251-5, 25

**AMOUNT:** 5 mg, 25 mg

STRUCTURE:

MOLECULAR FORMULA: C<sub>17</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub>

MOLECULAR WEIGHT: 296.32

**CAS NUMBER:** 950762-95-5

**APPEARANCE:** White to off-white solid

**SOLUBILITY**: DMSO (>20 mg/ml)

**PURITY:** ≥95% by HPLC

STORAGE: At -20°C. Protect from light and moisture

**DESCRIPTION:** Cell-permeable. A potent histone deacetylase 8 (HDAC8)

inhibitor (IC $_{50}$  = 0.01 µM) with >200-fold selectivity over HDAC isoforms 1, 2, 3, 6, and 10 (IC $_{50}$ s = 4, >50, >50, 2.9, and 13 µM, respectively). It inhibits cell growth and induces apoptosis only in T-cell-derived tumor lines, such as Jurkat and Hut78, but not in solid tumor lines, or in other hematopoietic tumors such as those derived from B cells, plasma cells or

monocytes.

**REFRENCE:** Balasubramaniam, S., et al. (2008). Leukemia 22, 1026-1034.

**HANDLING:** Do not take internally. Wear gloves and mask when handling

the product! Avoid contact by all modes of exposure.

**RELATED PRODUCTS:** 

CI-994 (Cat. No. 1742-10, 50) CUDC-101 (Cat. No. 1966-5, 25)

Depudecin (Cat. No. 2087-100)

DiscoveryPak™ HDAC Inhibitor Set (Cat. No. K851-6)

DiscoveryPak™ HDAC Inhibitor Set II (Cat. No. K876-7)

M344 (Cat. No. 1701-1)

MS-275 (Entinostat, MS-275) (Cat. No. 1590-1,5)

Nexturastat A (Cat. No. 2098-1) Nullscript (Cat. No. 2186-1) Oxamflatin (Cat. No. 2250-1, 5)

Panobinostat (LBH589) (Cat. No. 1612-1,5)

SAHA (Cat. No. 1604-1) SBHA (Cat. No. 2202-50, 250)

Sodium 4-phenylbutyrate (Cat. No. 1608-100,1000)

Sodium Butyrate (Cat. No. 1609-1000)

Splitomycin (Cat. No. 1610-5)
Trichostatin A (Cat. No. 1606-1)
Tubacin (Cat. No. 1984-250, 1000)
Tubastatin A (Cat. No. 1724-1, 5)

USAGE: FOR RESEARCH CH USE ONLY! Not to be used in

humans